

# TOP 20 PHARMA

## 1 Astellas

3-11, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, Japan 103-8411  
Tel: (81) 3 3244 3000 Fax: (81) 3 3244 3272  
[www.astellas.com](http://www.astellas.com)

<b>HEADCOUNT</b>	13,666
<b>YEAR ESTABLISHED</b>	2005
<b>PHARMA REVENUES</b>	\$8,530 +8%
<b>TOTAL REVENUES</b>	\$8,539 +8%
<b>NET INCOME</b>	\$1,558 +39%
<b>R&amp;D BUDGET</b>	\$1,181 -18%

### DRUGS APPROVED/LAUNCHED

<i>Drug</i>	<i>Indication</i>
mycamine	candidemia
advagraf	transplant rejection (EU)
celecox	rheumatoid arthritis (Japan)
vaprisol	hypervolemic hyponatremia

### DRUGS PENDING APPROVAL

<i>Drug</i>	<i>Indication</i>
fk506	organ rejection
mycamine	candidiasis (EU)
prograf	ulcerative colitis (Japan)

### DRUGS IN PHASE IIB AND BEYOND

<i>Drug</i>	<i>Indication</i>
ym178	urinary bladder, overactive
conivaptan	hyponatremia

tacrolimus  
zolpidem MR  
myasthenia gravis  
insomnia; schizophrenia;  
manic-depressive psychosis

### DRUGS COMING OFF PATENT

<i>Drug</i>	<i>Indication</i>
flomax	benign prostatic hyperplasia (2009)

### TOP SELLING DRUGS

<i>Drug</i>	<i>Indication</i>	<i>\$</i>	<i>(+/- %)</i>
Prograf	transplantation	\$1,782	19%
Harnal	BPH	\$1,075	-1%
Lipitor	cholesterol	\$858	6%
Micardis	hypertension	\$550	28%
Gaster	acid reflux	\$535	0%
Vesicare	bladder	\$528	70%

Account for 62% of total pharma sales, up from 59% in 2006.

## 18 Daiichi Sankyo

3-5-1 Nihombashi-honcho, Chuo-ku, Tokyo, 103-8426 Japan  
Tel: (81) 3 6255 1111 Fax: (81) 3 5255 7035  
[www.daiichisankyo.com](http://www.daiichisankyo.com)

<b>HEADCOUNT</b>	15,349
<b>YEAR ESTABLISHED</b>	2005
<b>PHARMA REVENUES</b>	\$7,382 +3%
<b>TOTAL REVENUES</b>	\$7,727 -3%
<b>NET INCOME</b>	\$858 +28%
<b>R&amp;D BUDGET</b>	\$1,436 -2%

### DRUGS APPROVED/LAUNCHED

<i>Drug</i>	<i>Indication</i>
welchol	type 2 diabetes
azor	high blood pressure

### DRUGS CANCELLED

<i>Drug</i>	<i>Indication</i>
cs-505	cholesterol

### DRUGS PENDING APPROVAL

<i>Drug</i>	<i>Indication</i>
prasugrel	acute coronary syndrome (with Lilly)

### DRUGS IN PHASE IIB AND BEYOND

<i>Drug</i>	<i>Indication</i>
cs-8635	cardiovascular diseases

olmetec  
rivoglitazone  
levofloxacin inj.  
denosumab  
memantine  
hydrochloride  
silodosin  
diabetic neuropathy  
metabolic disorders  
infectious diseases (Japan)  
bone/joint disease  
severe dementia/Alzheimer's  
benign prostatic hyperplasia

### TOP SELLING DRUGS

<i>Drug</i>	<i>Indication</i>	<i>\$</i>	<i>(+/- %)</i>
Olmesartan	hypertension	\$1,674	22%
Levofloxacin	anti-infection	\$930	4%
Pravastatin	cholesterol	\$655	-18%

Account for 44% of total pharma sales, up from 43% in 2006.

# TOP 20 PHARMA

**10** Eisai

4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 112-8088, Japan  
Tel: (81) 3 3817 3700 Fax: (81) 3 3811 3077  
[www.eisai.co.jp](http://www.eisai.co.jp)

<b>HEADCOUNT</b>	10,686
<b>YEAR ESTABLISHED</b>	2005
<b>PHARMA REVENUES</b>	\$6,250 +12%
<b>TOTAL REVENUES</b>	\$6,447 +12%
<b>NET LOSS*</b>	\$149
<b>R&amp;D BUDGET</b>	\$1,979 +114%

\* Net loss due to acquisition of MGI Pharma

## DRUGS APPROVED/LAUNCHED

Drug	Indication
aloxi	prevention of postoperative nausea and vomiting
fragmin	symptomatic venous thromboembolism in cancer patients - additional indication
aciphex	gastroesophageal reflux disease - pediatric

## DRUGS PENDING APPROVAL

Drug	Indication
aricept	severe Alzheimer's disease
rufinamide	epilepsy - adjunctive therapy

## DRUGS IN PHASE IIB AND BEYOND

Drug	Indication
e5564	critical care-severe sepsis

## EARLY RESEARCH PROJECTS

Drug	Indication
e5555	critical care-acute coronary syndrome
aciphex	gastrointestinal disorder - XR formulation
e7080	cancer-oral anti-cancer agent
e7974	cancer
e7820	cancer

## DRUGS COMING OFF PATENT

Drug	Indication
aricept	Alzheimer's disease (2010)

## TOP SELLING DRUGS

Drug	Indication	\$	(+/- %)
Aricept	Alzheimer's disease	\$2,549	18%
Aciphex	acid reflux	\$1,545	4%

Account for 65% of total pharma sales, same as in 2006.

**20** UCB Group

Allée de le Recherche 60, 1070 Brussels, Belgium  
Tel: (32) 2 559 9999 Fax: (32) 2 559 9900  
[www.ucb-group.com](http://www.ucb-group.com)

<b>HEADCOUNT</b>	12,102
<b>YEAR ESTABLISHED</b>	1928
<b>PHARMA REVENUES*</b>	\$4,370 +60%
<b>TOTAL REVENUES</b>	\$4,370 +55%
<b>NET INCOME</b>	\$219 -52%
<b>R&amp;D BUDGET</b>	\$1,080 +40%

\* 2007 results include full year of Schwarz Pharma revenues

## DRUGS APPROVED/LAUNCHED

Drug	Indication
keppra	epilepsy - pediatric
cimzia	Crohn's disease
xyzal oral solution	allergies, chronic idiopathic urticaria

## DRUGS PENDING APPROVAL

Drug	Indication
neupro	restless legs syndrome (EU)
vimpat	diabetic neuropathic pain, epilepsy (EU)
cimzia	rheumatoid arthritis

## DRUGS IN PHASE IIB AND BEYOND

Drug	Indication
cmc544	NHL
keppra XR	epilepsy monotherapy
vimpat	epilepsy monotherapy

rikelta	epilepsy; Unverricht Lundborg Disease
xyrem	fibromyalgia

## DRUGS COMING OFF PATENT

Drug	Indication
keppra	epilepsy (2008)
zyrtec	allergy (2007)

## TOP SELLING DRUGS

Drug	Indication	\$	(+/- %)
Keppra	epilepsy	\$1,406	47%
Zyrtec	antihistamine	\$668	-5%
Xyzal	antihistamine	\$230	28%
Omeprazole	ulcers, esophagitis	\$201	-16%
Tussionex	cough	\$156	18%
Nootropil	cognitive enhancer	\$138	11%

Account for 64% of total pharma sales, down from 85% in 2006.